Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, M. A. von Wichmann, Esteban Ribera et al.|Clinical Infectious Diseases|2017Cited by 103
Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient CharacteristicsJuan Berenguer, Carmen Quereda, J. Marta Moreno et al.|Open Forum Infectious Diseases|2016Cited by 42
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1Natalia Stella-Ascariz, Rocío Montejano, Javier Rodríguez-Centeno et al.|The Journal of Infectious Diseases|2018Cited by 33
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, Estebán Martínez, José L Blanco et al.|The Lancet HIV|2025Cited by 22
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical TrialRocío Montejano, Fernando Calle, María Velasco et al.|Clinical Infectious Diseases|2022Cited by 20